TheranosticTrials.org

Clinical Trial · NCT02441972

Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

Overview

The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.

Sponsor

Sichuan Provincial People's Hospital

Phase

Phase 1

Contacts

Chunjing Yu, Dr. (CONTACT)

ycj_wxd1978@163.com

86-15312238622

Weixing Wan, Professor (STUDY_CHAIR)

ClinicalTrials.gov

NCT02441972

Drug / Compound

PRGD2

Isotope(s):
Target(s):
  • αvβ3
Ligand Class: Peptides
Chelator: NOTA
Linker: Al

Eligibility

Inclusion

  • The patients have been diagnosed with cancer or suspected with cancer;

Exclusion

  • Hypersensitive to the active or inactive ingredients of the study drug;
  • Hepatic and renal function insufficiency;
  • Having attended other drug clinical trials within three months;
  • Cardiac functional insufficiency;